JD Health International, Inc. (6618) AI Stock Analysis

• Market Cap: HK$204.91B
• Dividend Yield: N/A
• Average Volume (3M): 7.60M
• Price to Earnings (P/E): 39.5
• Beta (1Y): 1.44
• Revenue Growth: 18.56%
• EPS Growth: 79.54%
• Country: HK
• Employees: 3,564
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.90
• Shares Outstanding: 3,209,275,100
• 10 Day Avg. Volume: 6,883,323
• 30 Day Avg. Volume: 7,596,953
• PEG Ratio: 0.21
• Price to Book (P/B): 1.51
• Price to Sales (P/S): 1.43
• P/FCF Ratio: 19.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$77.61
• Price Target Upside: 25.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: HK$70.00 ▲(12.81% Upside)

JD Health International, Inc. demonstrates strong financial performance and a positive outlook from its recent earnings call, which are the most significant factors driving the stock's score. Technical analysis indicates mixed signals, with short-term weakness but longer-term strength. The valuation suggests the stock is relatively expensive, which slightly tempers the overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective business strategies, supporting long-term financial health and expansion.

Active User Growth

Growing active user base enhances JD Health's market position and potential for increased service adoption, driving sustainable revenue streams.

AI Integration

Integration of AI technologies boosts operational efficiency and user satisfaction, positioning JD Health as a leader in tech-driven healthcare solutions.

Negative Factors

Increased Expenses

Rising expenses could pressure margins, requiring careful management to maintain profitability while pursuing growth initiatives.

Operating Cash Flow Decline

Decreased operating cash flow may impact JD Health's ability to fund operations and growth, necessitating improved cash management strategies.

Expense Ratio Increase

An increase in the expense ratio could affect JD Health's cost efficiency, potentially impacting long-term profitability if not addressed.

JD Health International, Inc. Business Overview & Revenue Model

Company Description

JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.

How the Company Makes Money

JD Health generates revenue through multiple streams. The primary revenue sources include online pharmaceutical sales, where the company earns margins from selling prescription and over-the-counter medications. Additionally, JD Health provides telehealth services, charging fees for virtual consultations with healthcare professionals. The company also offers health management and wellness services, with subscription models for ongoing care and monitoring. Significant partnerships with pharmaceutical companies and health institutions enhance its product offerings and expand its reach, while leveraging JD.com's vast logistics and e-commerce infrastructure further supports its revenue growth.

JD Health International, Inc. Financial Statement Overview

Summary

JD Health International, Inc. presents a compelling financial profile with strong revenue growth, improved profitability, and a stable balance sheet. The company has effectively managed its debt levels, ensuring financial stability. Cash flow generation remains robust, supporting its operations and growth initiatives.

Income Statement

JD Health International, Inc. has demonstrated strong revenue growth over the years, with a notable increase from 2019 to 2024. Gross profit margins have remained healthy, reflecting efficient cost management. The net profit margin has improved significantly, turning from losses in earlier years to profitable outcomes in recent periods, showcasing strong profitability. EBIT and EBITDA margins have shown positive trends, indicating enhanced operational efficiency.

Balance Sheet

The company's balance sheet is robust, characterized by a high equity ratio, which indicates strong financial stability and low reliance on debt. The debt-to-equity ratio is low, suggesting prudent financial management and reduced financial risk. Return on equity has improved significantly, reflecting better utilization of shareholders' funds.

Cash Flow

JD Health International exhibits a solid cash flow position, with consistent operating cash flow generation. Free cash flow growth has been positive, indicating strong cash generation capabilities. The operating cash flow to net income ratio is healthy, underscoring efficient cash conversion. However, a slight decline in operating cash flow compared to the previous year is a point of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	65.11B	58.16B	53.53B	46.74B	30.68B	19.38B
Gross Profit	15.50B	13.31B	11.87B	9.89B	7.20B	4.92B
EBITDA	2.49B	1.31B	2.93B	-60.93M	-1.37B	-17.04B
Net Income	4.72B	4.16B	2.14B	380.11M	-1.07B	-17.23B
Balance Sheet
Total Assets	78.46B	71.27B	64.29B	61.28B	48.00B	43.99B
Cash, Cash Equivalents and Short-Term Investments	49.31B	51.24B	41.22B	47.67B	41.99B	40.30B
Total Debt	429.69M	258.39M	214.75M	199.41M	201.27M	89.98M
Total Liabilities	20.48B	16.03B	14.92B	16.49B	8.15B	4.74B
Stockholders Equity	57.97B	55.23B	49.36B	44.78B	39.85B	39.25B
Cash Flow
Free Cash Flow	8.32B	4.29B	4.54B	5.86B	2.93B	3.68B
Operating Cash Flow	8.35B	4.33B	4.60B	5.91B	3.43B	3.70B
Investing Cash Flow	7.96B	3.15B	-8.02B	-4.24B	-17.75B	-7.84B
Financing Cash Flow	-54.11M	-45.61M	-117.20M	-925.45M	-163.65M	32.03B

JD Health International, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 62.05
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6618, the sentiment is Positive. The current price of 62.05 is above the 20-day moving average (MA) of 58.20, above the 50-day MA of 60.87, and above the 200-day MA of 51.82, indicating a bullish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 58.65 is Neutral, neither overbought nor oversold. The STOCH value of 87.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6618.

JD Health International, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6618	75 Outperform	HK$204.91B	39.53	8.52%	―	18.56%	79.54%
3689	71 Outperform	HK$601.91M	7.29	5.33%	9.14%	0.47%	50.46%
1526	66 Neutral	HK$1.57B	5.42	20.47%	4.37%	-3.56%	-17.45%
2273	66 Neutral	HK$7.15B	19.34	14.86%	2.61%	16.41%	32.97%
6078	62 Neutral	HK$8.66B	17.61	6.78%	―	-13.92%	-36.32%
1951	55 Neutral	HK$6.89B	-6.61	-9.67%	2.38%	-8.56%	-403.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JD Health International, Inc. Corporate Events

JD Health International Approves Key Agreements at Extraordinary General Meeting

JD Health International, Inc. announced the successful approval of all proposed resolutions during its Extraordinary General Meeting held on December 8, 2025. The resolutions include agreements with JD.com for technology and traffic support services and the provision of healthcare products and services, which are expected to strengthen the company’s operational capabilities and market position.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$70.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Expands Strategic Partnerships and Reports Strong Q3 Growth

JD Health International Inc. has announced strategic partnerships with major pharmaceutical companies and launched innovative drugs and health products online, reinforcing its position as a leading online marketplace for new and specialty medicines. The company also formed an intelligent interconnected ecosystem alliance with medical device brands to develop a comprehensive smart health management system. Additionally, JD Health has collaborated with Union Hospital to establish an intelligent outpatient service platform, enhancing its ‘Internet + healthcare’ services. Financially, JD Health reported significant growth in revenue and profit for the third quarter of 2025, highlighting its strong performance and market expansion.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$66.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health to Hold EGM for Strategic Agreements with JD.com

JD Health International Inc. has announced an extraordinary general meeting to be held on December 8, 2025, to approve several agreements with JD.com. These agreements include the provision of technology and traffic support, healthcare products and services, marketing services, and integrated supply chain solutions, with transactions and annual caps set for the next three years. This move is expected to strengthen JD Health’s operational capabilities and market positioning, potentially impacting stakeholders by enhancing service offerings and efficiency.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$66.00 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health Grants Share Awards to Employees to Boost Growth

JD Health International, Inc. announced the grant of 299,090 Award Shares to its employees under the Post-IPO Share Award Scheme, representing about 0.01% of the total issued shares. This initiative aims to align employee interests with the company’s growth and profitability, encouraging long-term contributions. The shares will vest over periods ranging from 0.25 to 4 years, with no performance targets attached, and include a clawback mechanism to protect the company’s interests. This move is expected to strengthen employee retention and commitment, potentially impacting the company’s operational efficiency and market positioning positively.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.

JD Health International Announces Board Composition and Roles

JD Health International Inc. has announced the composition of its board of directors, highlighting the roles and functions of its executive, non-executive, and independent non-executive directors. This announcement provides insights into the company’s governance structure, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (HK:6618) stock is a Buy with a HK$78.50 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.